PolyPid Ltd. (PYPD) Prices 3.75M Share IPO at $16/Sh

PolyPid Ltd. (NASDAQ: PYPD), a Phase 3 clinical-stage pharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, announced the pricing of its initial public offering of 3,750,000 ordinary shares at a price to the public of $16.00 per share, for gross proceeds of $60.0 million. All of the ordinary shares are being offered by PolyPid.

The shares are expected to begin trading on The Nasdaq Global Market under the symbol "PYPD" on June 26, 2020. The offering is expected to close on June 30, 2020, subject to customary closing conditions. In addition, PolyPid has granted the underwriters a 30-day option to purchase up to 562,500 additional ordinary shares at the initial public offering price less underwriting discounts and commissions.

Barclays and BMO Capital Markets acted as joint book-running managers. Raymond James acted as lead manager. National Securities Corporation, ODDO BHF and A.G.P/Alliance Global Partners acted as co-managers.

You May Also Be Interested In

• River City Bank completes $121.5M secondary IPO on Nasdaq
• Attovia Therapeutics raises $332.4M in Nasdaq IPO
• Latigo Biotherapeutics prices $345.6M IPO at $18 per share